🧠Overactive Brain Cells Linked to Sleep Loss in Alzheimer's
Sleep problems in Alzheimer's may be treatable
TL;DR
Scientists found that overactive immune cells in the brain cause sleep loss in Alzheimer's, and temporarily removing these cells restored over two hours of sleep in mice. This could lead to new treatments for sleep issues in Alzheimer's patients.
Scientists have discovered that overactive immune cells in the brain are a major cause of sleep loss in Alzheimer's disease. By temporarily removing these cells, researchers were able to restore more than two hours of sleep per day in mice. This finding challenges the prevailing understanding that amyloid plaques are the primary cause of sleep problems in Alzheimer's. The study, published in Alzheimer's & Dementia, suggests a potential new approach to treating one of the most disruptive symptoms of the disease. Researchers used advanced technologies like EEG and light-sheet microscopy to measure sleep and examine brain activity, and found that sleep problems did not worsen as amyloid plaques accumulated.
Key Points
Researchers at the University of Kentucky used Pexidartinib (PLX3397) to temporarily eliminate most of the brain's immune cells, resulting in an 87% depletion of microglia.
The study, led by Shannon L. Macauley, Ph.D., and first author Nicholas J. Constantino, Ph.D., was published in Alzheimer's & Dementia on October 19, 2026.
Advanced technologies like EEG and electromyography (EMG) were used to measure sleep and examine brain activity in mice.
Light-sheet microscopy was used to visualize the relationship between amyloid plaques and immune cells throughout the brain.
The drug Pexidartinib was administered to mice for 14 days, allowing researchers to observe the effects on sleep and brain activity.
Why It Matters
If you're working on Alzheimer's treatments, this study challenges the focus on amyloid plaques and suggests a new pathway for addressing sleep issues. The findings could lead to new drug targets and therapies that improve sleep quality in patients, potentially slowing disease progression.
Comments
Be the first to comment
Enjoyed this article?
Get it daily. 7am. Free. Reads in 5 minutes.